← All Neuraxis, INC filings

Neuraxis, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
NRXS
Neuraxis, INC
10-K: Neuraxis Reports Revenue Growth Amidst Persistent Losses
Neuraxis, Inc. reported increased net sales for 2025, driven by product adoption, but continues to face substantial operating losses and going concern doubts.
AMEX
NRXS
Neuraxis, INC
10-K: Neuraxis, Inc. Reports Financial Results for Fiscal Year 2024; Highlights Growth Strategy and Pipeline Development
Neuraxis, Inc. reports its 10-K filing, detailing its financial results for the fiscal year ended December 31, 2024, and outlining its business strategy focused on neuromodulation therapies, pipeline development, and regulatory compliance.
AMEX
NRXS
Neuraxis, INC
10-K: Neuraxis, Inc. Details Share Structure and Regulatory Landscape in 10-K Filing
Neuraxis, Inc.'s 10-K filing provides a comprehensive overview of its share structure, regulatory environment, and business operations, highlighting its focus on neuromodulation therapies.